May 11, 2011
/PRNewswire/ -- Today, Cephalon, Inc. (NASDAQ: CEPH) recognizes those who stay awake to keep our society moving while the rest of us are sleeping by honoring National Night Shift Workers Day and introducing a new video, "Shift Your Assumptions," as a tribute to shift workers. According to the U.S. Department of Labor, over 15 million Americans work odd hours or non-traditional shifts and may be at risk for a medical condition called shift work disorder, in which their body's clock is out of sync with their work schedule. As part of The Wake-Up Squad(SM), a national disease awareness initiative developed by Cephalon to educate community members about health concerns related to shift work disorder, the Company encourages the public to recognize those who work non-traditional hours by thanking a shift worker and sharing with family and friends the new two-minute video, "Shift Your Assumptions." To access the video and learn more about shift work disorder visit
Up to 25 percent of people who work night or rotating-shifts are estimated to have shift work disorder, a medical condition in which the body's internal sleep-wake clock is out of sync with the individual's work schedule—their body is telling them to go to sleep when their work schedule needs them to stay awake. Because of this disruption of the body's natural rhythm, people with shift work disorder often struggle to stay awake during their waking hours (excessive sleepiness), or have trouble sleeping during their sleeping hours (insomnia).
About The Wake-Up Squad
The Wake-Up Squad is an award-winning educational program designed to motivate and mobilize community members about shift work disorder. The website features information about shift work disorder and provides tools, such as a symptom checklist, to help prepare for a discussion with a healthcare professional. In addition, Community Educators trained to talk about shift work disorder are in various cities and communities across the country. To learn more about shift work disorder or to register to take a self-assessment, visit
About Cephalon, Inc.
Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries. More information on Cephalon and its products is available at
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide the Cephalon current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.
SOURCE Cephalon, Inc.